In a significant leap forward for cardiovascular care, Brightflow SAS has successfully raised €16.5 million in Series A funding. This impressive round of equity investment is set to propel the company’s groundbreaking efforts in developing a minimally invasive solution for end-stage heart failure.
Based in France, Brightflow SAS is at the forefront of innovation in mechanical circulatory support. Their focus is on a fully percutaneous, long-term right ventricular (RV) support system designed to address severe RV dysfunction—a condition affecting millions across Europe and the United States. Unlike traditional mechanical support, which involves high peri-operative mortality rates, Brightflow’s approach promises a safer, less invasive alternative with the potential to significantly improve patient outcomes.
Sophie Humbert, CEO of Brightflow SAS, emphasized the milestone achievement: “This financing underscores not only the strength of our technology but also our commitment to developing the first long-term blood pump that can be implanted without the need for open-heart surgery.” The funding round, which attracted new investors including VIVES Partners, Majycc Innovation Santé – UI Investissement, and BNP Paribas Development, also saw continued support from existing backers GO Capital and Karista.
Philippe Durieux, Managing Partner at VIVES Partners, praised the initiative, stating, “Brightflow has assembled a world-class team, and we believe in their capability to translate their innovative approach into a commercial success.” David Moreau, Investment Director at BNP Paribas Development, added, “As long-term investors, we are excited to support a team led by seasoned medtech executives, including CEO Sophie Humbert and CTO Lars Bredenbreuker. We are confident that their vision will soon lead to successful human implantations.”
The Series A funding will facilitate key strategic initiatives through early 2026, encompassing the final stages of product development and the commencement of compassionate implantations.
Editorial Opinion:
Brightflow SAS is poised to make a substantial impact on the cardiovascular medical device industry. Their innovative approach to treating severe right ventricular dysfunction is not merely a technical advancement but a potential game-changer in patient care. The high mortality rates associated with traditional mechanical support underscore the critical need for safer, minimally invasive options—a gap that Brightflow’s technology aims to fill.
The strategic focus on a fully percutaneous solution represents a forward-thinking approach that aligns with broader trends in medical device innovation. Minimally invasive procedures are increasingly favored for their reduced risk profiles and faster recovery times, making Brightflow’s solution particularly timely and relevant. As the company progresses towards human trials and eventual commercialization, it is well-positioned to redefine standards of care in heart failure management.
The involvement of prominent investors and the backing of a highly skilled team further validate Brightflow’s promising trajectory. If successful, this venture could not only enhance the quality of life for countless patients but also establish new benchmarks for the industry.
For additional information or corrections, please contact us at editor@thetimesmag.com.
